Altria Writes Down Juul Stake to Under $500M as FDA Ban Looms

Last updated: October 13, 2026

Altria's bet on Juul has officially gone from billion-dollar growth story to rounding error. The Marlboro maker slashed the value of its 35% stake in the e-cigarette company to under $500 million in its latest quarterly filing, down from $1.6 billion.

According to the Associated Press, the write-down reflects the prospect of a US ban on Juul's small cartridge-based e-cigarettes. The FDA announced last month that it plans to pull Juul's products from the market, though a federal court has since paused that order while the agency reconsiders.

Key facts

• Altria invested $12.8 billion for a 35% stake in Juul in 2018.
• The stake is now valued at under $500 million.
• Previously, Altria had marked the stake at $1.6 billion.
• The FDA announced plans to ban Juul's cartridge e-cigarettes in June.
• A federal court has blocked the immediate ban while the FDA reopens its review.

How the deal went sideways

In late 2018, Altria paid $12.8 billion for a 35% stake in Juul, then the hottest name in vaping. The thesis was simple: cigarettes were declining, Juul was growing, and Altria needed a path to the next generation of nicotine users.

Since then, regulators have pushed back hard. Last month, the FDA moved to order Juul off the US market over questions about the chemistry data behind its nicotine pods. That move caught industry observers off guard, since the agency had greenlit several rival e-cigarettes, and Juul had spent years assembling its scientific dossier.

Our analysis

This is one of the most dramatic corporate impairments of the last decade, and the timing could hardly be worse. The investment was supposed to be Altria's bridge from combustible cigarettes to next-gen nicotine. Instead it turned into a drag on the balance sheet the company still cannot fully shed.

The overlooked piece is the non-compete. Altria agreed not to market competing vaping products as long as it holds the stake. Even now, with the position effectively wiped out, Altria cannot easily spin up a rival device to claw value back.

The FDA's reversal is the swing factor. A court blocked the original ban, and the agency has reopened its review. If Juul wins back authorization, the stake recovers enough to shrink the impairment. If the ban holds, the remaining book value heads to zero. That binary is exactly why Altria is keeping the position rather than selling at fire-sale prices.

What it means for you

For investors, the takeaway is blunt. "Too big to write off" can still mean writing most of it off. Altria's stock will increasingly trade on cigarette volumes, pricing power, and dividend stability, not on Juul optionality. Rival e-cigarette makers like NJOY and British American Tobacco's Vuse now sit on a regulatory moat the FDA just handed them.

For consumers and retailers, the immediate question is shelf availability. For now, Juul products remain for sale while the agency reconsiders. The next twelve months will determine whether Juul is a regulated nicotine product on equal footing with competitors or a cautionary case study.

Say you are an Altria shareholder reviewing the quarter: the headline number is the cigarette business, not the Juul line. The Juul stake is now small enough that an outright sale, or a full impairment, will not move the stock much. What matters from here is how Altria redirects the capital it can no longer deploy into vape.

What to watch next

• The FDA's reopened review of Juul's application and any public timeline.
• Whether Altria pushes to renegotiate the non-compete clause.
• Market share data from authorized competitors like Vuse and NJOY.

Bottom line: Altria is holding a wrecked investment because the contract says it must. The real question now is whether the FDA's reversal gives the company any realistic path back.